Immuno-Efficacy of a T. gondii Secreted Protein with an Altered Thrombospondin Repeat (TgSPATR) As a Novel DNA Vaccine Candidate against Acute Toxoplasmosis in BALB/c Mice.
Immuno-Efficacy of a T. gondii Secreted Protein with an Altered Thrombospondin Repeat (TgSPATR) As a Novel DNA Vaccine Candidate against Acute Toxoplasmosis in BALB/c Mice.
复制标题
具有改变的血小板反应蛋白重复序列 (TgSPATR) 的弓形虫分泌蛋白作为针对 BALB/c 小鼠急性弓形虫病的新型 DNA 候选疫苗的免疫功效
DOI：
10.3389/fmicb.2017.00216
复制
发表时间：
2017
影响因子：
5.2
通讯作者：
Lu S
中科院分区：
文献类型：
--
作者：
Zheng B;Ding J;Chen X;Yu H;Lou D;Tong Q;Kong Q;Lu S
弓形虫（Toxoplasma gondii，T.gondii）分布于世界各地，感染包括人类在内的大多数温血动物。弓形虫病具有严重的后果，特别是在免疫系统受损或不成熟的人中。因此，迫切需要一种有效的疫苗。分泌型微线体蛋白是T.刚地。编码微线体蛋白的基因T.弓形虫TgSPATR基因的重组质粒pVAX 1-TgSPATR，经肌肉注射BALB/c小鼠，观察其诱导的免疫应答。淋巴细胞增殖试验、细胞因子（IFN-γ、IL-2、IL-4、IL-10）和抗体测定表明，pVAX 1-TgSPATR免疫小鼠产生了体液和混合型Th 1/Th 2细胞免疫应答。pVAX 1-TgSPATR免疫组小鼠的存活时间（15.7 ± 1.42天）也明显延长（p < 0.05）。目前的研究表明，pVAX 1-TgSPATR诱导T.弓形虫特异性免疫应答，有望成为弓形虫病疫苗候选者。据我们所知，这是第一个报告，以评估免疫保护价值的TgSPATR对T。刚地。
Toxoplasma gondii (T.gondii) is distributed worldwide and infects most species of warm-blooded animals, including humans. Toxoplasmosis has serious consequences, especially in people with an impaired or immature immune system. Thus, an effective vaccine is urgently required. Secretory microneme proteins are essential for the adhesion and invasion of T. gondii. The gene encoding the microneme protein, T. gondii secreted protein with an altered thrombospondin repeat (TgSPATR), we constructed a recombinant eukaryotic plasmid, pVAX1-TgSPATR, as a DNA vaccine, injected it intramuscularly into BALB/c mice and evaluated the induced immune response. Lymphocyte proliferation assays, cytokine (IFN-γ, IL-2, IL-4, IL-10), and antibody determinations showed that mice immunized with pVAX1-TgSPATR produced humoral and mixed Th1/Th2 type cellular immune responses. The survival times of mice immunized with pVAX1-TgSPATR were also significantly prolonged (15.7 ± 1.42 days) compared with control groups, which died within 7 days of challenge (p < 0.05). The current study indicated that pVAX1-TgSPATR induce a T. gondii specific immune response and might be a promising vaccine candidate against toxoplasmosis. To the best of our knowledge, this is the first report to evaluate the immunoprotective value of TgSPATR against T. gondii.